PubRank

J A Lowe

Author PubWeight™ 48.56‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A potent nonpeptide antagonist of the substance P (NK1) receptor. Science 1991 4.06
2 Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995 1.57
3 The scope of unmet maternal health needs in pediatric settings. Pediatrics 1999 1.46
4 Studies on rabbit lymphocytes in vitro. XI. Superaddition of anti-allotypic lymphocyte transformation: evidence for multipotent lymphoid cells. J Immunol 1970 1.32
5 Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats. Psychopharmacology (Berl) 1996 1.29
6 Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys. J Pharmacol Exp Ther 1995 1.28
7 Humoral and cellular aspects of immunoglobulin allotype suppression in the rabbit. I. Kinetics of neutralization of suppression. Immunology 1973 1.25
8 Different binding epitopes on the NK1 receptor for substance P and non-peptide antagonist. Nature 1993 1.21
9 Biological monitoring of agricultural workers exposed to pesticides: I. Cholinesterase activity determinations. J Occup Med 1986 1.20
10 Activity and distribution of binding sites in brain of a nonpeptide substance P (NK1) receptor antagonist. Science 1991 1.17
11 Immunogenic and antigenic epitopes of immunoglobulins--V. Reactivity of a panel of monoclonal antibodies with sub-fragments of human Fc gamma and abnormal paraproteins having deletions. Mol Immunol 1983 1.15
12 CB1 receptor antagonist precipitates withdrawal in mice exposed to Delta9-tetrahydrocannabinol. J Pharmacol Exp Ther 1998 1.12
13 Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A. Eur J Pharmacol 1995 1.00
14 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem 1996 0.97
15 Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal. J Pharmacol Exp Ther 1996 0.97
16 Mechanism of allotype suppression in the rabbit. Transplant Rev 1975 0.95
17 Antiinflammatory and analgesic activity of a non-peptide substance P receptor antagonist. Eur J Pharmacol 1992 0.95
18 The activity of homologous and heterologous anti-allotypic sera in transformation and allotypic suppression in rabbits. Immunology 1972 0.94
19 Effect of CP-96,345, a nonpeptide substance P receptor antagonist, on salivation in rats. Proc Natl Acad Sci U S A 1991 0.92
20 Need we revive falling autopsy rates? Time trends in PAS hospitals in the United States. PAS Rep 1977 0.92
21 Molecular basis for the species selectivity of the substance P antagonist CP-96,345. J Biol Chem 1993 0.91
22 Characterization of non-peptide antagonist and peptide agonist binding sites of the NK1 receptor with fluorescent ligands. J Biol Chem 1997 0.91
23 Humoral and cellular aspects of immunoglobulin allotype suppression in the rabbit. II. Effect of beta locus suppression on immunoglobulin receptor-bearing lymphocytes. Immunology 1974 0.90
24 Biological monitoring of agricultural workers exposed to pesticides: II. Monitoring of intact pesticides and their metabolites. J Occup Med 1986 0.89
25 Immunogenic and antigenic epitopes of immunoglobulins--VII. The topographical distribution of Fc gamma epitopes and the relationship of an iso-allotypic specificity to the presence of histidine 435. Mol Immunol 1984 0.89
26 Photoaffinity labeling of the human substance P (neurokinin-1) receptor with [3H2]azido-CP-96,345, a photoreactive derivative of a nonpeptide antagonist. Mol Pharmacol 1996 0.86
27 Two nonpeptide tachykinin antagonists act through epitopes on corresponding segments of the NK1 and NK2 receptors. Proc Natl Acad Sci U S A 1993 0.85
28 Predictions of extreme precipitation and sea-level rise under climate change. Philos Trans A Math Phys Eng Sci 2002 0.85
29 Studies on rabbit lymphocytes in vitro. XII. Augmentation of anti-allotypic blast transformation by a second anti-allotypic serum directed against the primary stimulating anti-allotypic serum (piggy-back effect). J Immunol 1970 0.84
30 The concentration of creatine in meat, offal and commercial dog food. Res Vet Sci 1997 0.84
31 PASport. Use of Professional Activity Study (PAS) data to focus medical care evaluation studies. QRB Qual Rev Bull 1977 0.83
32 Immunogenic and antigenic epitopes of immunoglobulins. XVIII. Subpopulations of human lambda chains defined with a panel of monoclonal antibodies. Immunology 1986 0.83
33 Humoral and cellular aspects of immunologlobulin allotype suppression in the rabbit. III. Production of anti-allotypic antibody by suppressed animals. Immunology 1975 0.83
34 Dimensional stability of composite used as a core material. J Prosthet Dent 1986 0.82
35 Studies on rabbit lymphocytes in vitro. XVI. Restimulation of antiallotypically stimulated and blocked cultures. J Immunol 1973 0.82
36 Specific residues at the top of transmembrane segment V and VI of the neurokinin-1 receptor involved in binding of the nonpeptide antagonist CP 96,345 [corrected]. J Biol Chem 1994 0.82
37 Hematology and clinical chemistry parameters in the cat (Felis domesticus). J Nutr 1998 0.80
38 CP-96,345 antagonism of NK1 receptors and smoke-induced protein extravasation in relation to its cardiovascular effects. Eur J Pharmacol 1992 0.79
39 Selective inhibition of the carotid body sensory response to hypoxia by the substance P receptor antagonist CP-96,345. Proc Natl Acad Sci U S A 1993 0.78
40 Binding epitopes for peptide and non-peptide ligands on the NK1 (substance P) receptor. Regul Pept 1993 0.78
41 Studies on rabbit lymphocytes in vitro. XV. The effect of blocking serum on anti-allotypic lymphocyte transformation. J Immunol 1972 0.78
42 Cardiovascular effects of cholecystokinin-4 are mediated by the cholecystokinin-B receptor subtype in the conscious guinea pig and dog. J Pharmacol Exp Ther 1997 0.78
43 Synthesis of a nonpeptide carbon-11 labeled substance P antagonist for PET studies. Nucl Med Biol 1993 0.78
44 Film thickness measurements of a paint-on die spacer. J Prosthet Dent 1988 0.78
45 Variants of lymphoid lines produced with ricin A-chain monoclonal antibody conjugates. J Immunol Methods 1985 0.78
46 Humoral and cellular aspects of immunoglobulin allotype suppression in the rabbit. IV. Kinetics of induction. Immunology 1976 0.77
47 Dimensional stability of silver amalgam and composite used as core materials. J Prosthet Dent 1987 0.77
48 Changes in the phenotype and immunoglobulin secretion of human B cells following co-culture with cells of an EBV+ lymphoblastoid line or fusion with mouse plasmacytoma cells. Studies in short-term and long-term culture. Clin Exp Immunol 1989 0.75
49 BIRMA-K3, a new monoclonal antibody for CD34 immunophenotyping and stem and progenitor cell assay. J Hematother 1996 0.75
50 Denture flasking: a comparative study of three techniques. J Prosthet Dent 1982 0.75
51 Noise or fugue: seeking the logic of child health indicators. Ment Retard 1992 0.75
52 Selective blockade of sensory response of the carotid body to hypoxia by NK-1 receptor antagonist CP-96,345. Regul Pept 1993 0.75
53 Selecting a low-gold type III casting alloy. Gen Dent 1983 0.75
54 Correcting marginal defects of cast gold restorations. Gen Dent 1983 0.75
55 If it isn't documented, it isn't done. J Am Health Care Assoc 1979 0.75
56 Effect of die spacer on the seating of cast restorations on composite core preparations. J Prosthet Dent 1987 0.75
57 DRG's impact would hit MDs and medical records personnel. Hosp Peer Rev 1983 0.75
58 The anxieties of drug discovery and development. CCK-B receptor antagonists. Pharm Biotechnol 1998 0.75
59 Modelling the increased frequency of extreme sea levels in the Ganges-Brahmaputra-Meghna delta due to sea level rise and other effects of climate change. Environ Sci Process Impacts 2015 0.75
60 Relationship of prodigiosin condensing enzyme activity to the biosynthesis of prodigiosin and its precursors in Serratia marcescens. Experientia 1987 0.75
61 Use of the stereo microscope in fixed prosthodontics. J Dent Educ 1982 0.75
62 Tachykinin non-peptide antagonists: binding domain and molecular mode of action. Biochem Soc Trans 1995 0.75
63 Synthetic approaches to adriamycin involving Diels-Alder reactions of photochemically generated bisketenes. Total synthesis of islandicin and digitopurpone. J Org Chem 1977 0.75
64 Synthesis and structure-activity relationships of CP-122,721, a second-generation NK-1 receptor antagonist. Bioorg Med Chem Lett 1998 0.75
65 Absorption of creatine from meat or other dietary sources by the dog. Vet Rec 1995 0.75
66 Antiinflammatory and analgesic activity of CP-96,345: an orally active non-peptide substance P receptor antagonist. Regul Pept 1993 0.75
67 Clonal heterogeneity and other properties of auto anti-allotype antibodies produced in allotype-suppressed rabbits. Mol Immunol 1979 0.75
68 A study of well water in selected California communities for residues of 1,3-dichloropropene, chloroallyl alcohol and 49 organophosphate or chlorinated hydrocarbon pesticides. Bull Environ Contam Toxicol 1982 0.75